RE:If TH1902 does not work, we are done..YES or NO? Here's the interesting thing about the SORT1+ Platform. What they've stated from day one is what they want to prove with the science is they've found a way to deliver a more concentrated toxin to solid tumors overexpressing Sort1 but with a far better safety profile. Like some of the other ADC companies, they are not really discovering a new toxin, just a novel way to internalize many drugs into the tumor and not all around the body.
The trial is not so much about the toxin as it is the validity of the target, the internalization, the quick disposal of non-absorbed PDC, the construction of the PDC parts, etc... A few of these key elements we have tantalizing anecdotes about. It may end up being, as SPCEO said, that SN38 or siRNA ends up being even better. So we just need to see the key concepts to the platform work. It's hard, but a bit different than developing a new drug to kill a tumor cell.
TH1902 wrote: What do you all think?
Patiently here for years and feel like I've been strung along with promise after promise from this company.
I think if the Oncology program flops, its over...thoughts and opinions?
I would maybe prefer a partnership sooner than later to offset risk going forward...biotechs are hard...